We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-5.92%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
-$114M
Cap. Flow
+$174M
Cap. Flow %
6.13%
Top 10 Hldgs %
45.99%
Holding
98
New
13
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
BMEA icon
Biomea Fusion
BMEA
+$36.9M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$24.8M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$21.3M
4
GHRS icon
GH Research
GHRS
+$20.7M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$20.6M

Top Sells

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$27.2M
2
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$10.3M
3
VINCU
Vincerx Pharma, Inc. Unit
VINCU
+$8.1M
4
ACHL
Achilles Therapeutics
ACHL
+$2.6K

Sector Composition

Rank Sector Weight
1 Healthcare 97.6%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$323M 11.4%
2,000,000
– –
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$262M 9.25%
764,188
– –
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$171M 6.04%
2,075,905
– –
ITOS
4
DELISTED
iTeos Therapeutics
ITOS
$111M 3.93%
4,345,016
– –
RVMD icon
5
Revolution Medicines
RVMD
$39.9B
$111M 3.9%
3,484,264
– –
PMVP icon
6
PMV Pharmaceuticals
PMVP
$59.2M
$77.5M 2.73%
2,268,236
– –
RCKT icon
7
Rocket Pharmaceuticals
RCKT
$340M
$64.9M 2.29%
1,466,051
– –
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
$63.2M 2.23%
400,000
– –
SAGE
9
DELISTED
Sage Therapeutics
SAGE
$62.1M 2.19%
1,094,000
– –
RCUS icon
10
Arcus Biosciences
RCUS
$3.55B
$57.3M 2.02%
2,084,883
– –
SPRY icon
11
ARS Pharmaceuticals
SPRY
$509M
$51.8M 1.83%
1,675,377
– –
ARGX icon
12
argenx
ARGX
$54.6B
$51.5M 1.82%
170,926
– –
RLAY icon
13
Relay Therapeutics
RLAY
$4.1B
$47.4M 1.67%
1,294,132
– –
IDYA icon
14
IDEAYA Biosciences
IDYA
$3.42B
$46.2M 1.63%
2,202,812
– –
MRNS
15
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$43.1M 1.52%
2,400,000
– –
CYTK icon
16
Cytokinetics
CYTK
$10.5B
$41.6M 1.47%
2,100,000
– –
DBVT
17
DBV Technologies
DBVT
$799M
$41.2M 1.45%
753,460
– –
CNTB
18
Connect Biopharma Holdings
CNTB
$127M
$40.6M 1.43%
2,081,323
– –
NUVB icon
19
Nuvation Bio
NUVB
$2.2B
$40.4M 1.43%
4,341,009
– –
MRUS
20
DELISTED
Merus
MRUS
$40M 1.41%
1,900,000
– –
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.69B
$39.3M 1.39%
2,287,782
– –
ANAB icon
22
AnaptysBio
ANAB
$1.58B
$33.7M 1.19%
1,300,000
– –
BMEA icon
23
Biomea Fusion
BMEA
$84.6M
$32.6M 1.15%
+2,088,405
New +$36.9M
NRIX icon
24
Nurix Therapeutics
NRIX
$2.41B
$32.5M 1.15%
1,224,892
– –
ALGS icon
25
Aligos Therapeutics
ALGS
$26.2M
$31.1M 1.1%
61,042
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Boxer Capital held 98 positions worth $2.83B, down 3.9% from $2.95B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital deployed $174M of net new capital in Q2 2021, opening 13 new positions and adding to 2 existing holdings. Its largest new stake was Biomea Fusion: 2,088,405 shares worth $32.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Achilles Therapeutics, an estimated $2.6K trimmed.

  • Boxer Capital's largest Q2 2021 buy was Biomea Fusion: 2,088,405 shares worth $32.6M.
  • Boxer Capital added most to POINT Biopharma Global Inc. Common Stock in Q2 2021, an estimated $10.2M increase.
  • Boxer Capital's biggest Q2 2021 reduction was Achilles Therapeutics, cutting an estimated $2.6K.
  • Boxer Capital fully exited Direxion Daily S&P Biotech Bear 3X ETF in Q2 2021, selling an estimated $27.2M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.83B portfolio in Q2 2021.
  • Boxer Capital opened 13 new positions and closed 3 in Q2 2021.
  • Boxer Capital's portfolio value fell 3.9% quarter-over-quarter to $2.83B.

Based on Boxer Capital's 13F filing for Q2 2021, filed 16 Aug 2021.